{"id":"azd5004","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hyperphosphatemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"FGFR4 is frequently activated in hepatocellular carcinoma through FGF19 autocrine signaling, driving tumor growth and survival. By selectively inhibiting FGFR4, AZD5004 disrupts this oncogenic pathway, reducing proliferation and promoting apoptosis in FGFR4-dependent tumors. The selectivity for FGFR4 over other FGFR isoforms aims to minimize off-target toxicity.","oneSentence":"AZD5004 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF signaling in hepatocellular carcinoma and other cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:57:46.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), FGFR4-positive"}]},"trialDetails":[{"nctId":"NCT07455825","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Healthy Participants","enrollment":64},{"nctId":"NCT07444424","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-13","conditions":"Healthy Participants","enrollment":32},{"nctId":"NCT06942936","phase":"PHASE1","title":"A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-28","conditions":"Healthy Participants","enrollment":51},{"nctId":"NCT06579105","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-08","conditions":"Diabetes Mellitus, Type 2","enrollment":406},{"nctId":"NCT06988553","phase":"PHASE1","title":"A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eccogene","startDate":"2025-06-17","conditions":"Obesity or Overweight, Type 2 Diabetes","enrollment":45},{"nctId":"NCT06579092","phase":"PHASE2","title":"Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-08","conditions":"Obesity or Overweight","enrollment":310},{"nctId":"NCT06813781","phase":"PHASE1","title":"Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-12-19","conditions":"Hepatic Impairment","enrollment":33},{"nctId":"NCT06948747","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-06","conditions":"Healthy Participants","enrollment":49},{"nctId":"NCT06996886","phase":"PHASE1","title":"A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-22","conditions":"Healthy Participants","enrollment":16},{"nctId":"NCT06742762","phase":"PHASE1","title":"A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-12-17","conditions":"Renal Impairment","enrollment":16},{"nctId":"NCT06857695","phase":"PHASE1","title":"A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-03-06","conditions":"Healthy Participants","enrollment":8},{"nctId":"NCT06703658","phase":"PHASE1","title":"A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-11-02","conditions":"Healthy Participants, Type 2 Diabetes","enrollment":35},{"nctId":"NCT06555822","phase":"PHASE1","title":"A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-15","conditions":"Healthy Participants","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Active IMP","ECC5004","Dose 1"],"phase":"phase_2","status":"active","brandName":"AZD5004","genericName":"AZD5004","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD5004 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF signaling in hepatocellular carcinoma and other cancers. Used for Hepatocellular carcinoma (HCC), FGFR4-positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}